Why the study?
Does ticlopidine reduce events and improve tolerability compared to aspirin in patients with TIA?
Does ticlopidine reduce events and improve tolerability compared to aspirin in patients with TIA?
Ticlopidine 200 mg/day may reduce the long-term cumulative incidence of events and gastrointestinal side effects compared to aspirin 500 mg/day in patients with TIA.
Ticlopidine may reduce long-term events versus aspirin in TIA; extends antiplatelet comparisons despite mixed statistical significance.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tohgi et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: